麝香通心滴丸对冠状动脉微血管疾病患者微血管功能及生存质量的影响

Effect of Shexiang Tongxin Dropping Pill on Microvascular Function andLife Quality in Patients with Coronary Microvascular Disease

目的:观察麝香通心滴丸对冠状动脉微血管疾病患者微血管功能和生存质量的影响,并评价治疗安全性。方法:111例不合并阻塞性冠状动脉疾病的冠状动脉微血管疾病(coronary microvascular disease,CMVD)患者,随机分为治疗组(n=55)和对照组(n=56)。所有患者入组后记录西雅图心绞痛调查量表(Seattle angina questionnaire,SAQ)评分。对照组给予改善缺血症状、抗血小板及降脂等常规治疗,治疗组在对照组治疗基础上口服麝香通心滴丸,每次70 mg,每日3次。治疗6个月后复查冠状动脉血流储备(coronary flow reserve,CFR),采用SAQ评估患者生存质量。在服药治疗1个月、6个月后各测定1次安全性指标。结果:治疗6个月后两组CFR水平均显著改善(P<0.05),治疗组CFR水平优于对照组(P<0.05);治疗组CFR>2的患者比例高于对照组(29.1%vs 5.4%,P<0.05)。两组患者服药治疗后SAQ评分均显著升高(P<0.05);治疗组SAQ评分显著高于同期对照组(P<0.05)。两组治疗期间主要不良心血管事件发生率比较,差异无统计学意义(P>0.05)。两组治疗6个月后,心率及收缩压均显著降低(P<0.05);两组比较,差异无统计学意义(P>0.05)。结论:麝香通心滴丸可改善冠状动脉微血管疾病患者的微血管功能及生存质量,且治疗安全性好。

Objective:To observe the effect of Shexiang Tongxin Dropping Pill on microvascular function and quality of life in patients with coronary microvascular disease(CMVD),and to evaluate the safety of the treatment.Methods:111 CMVD patients without obstructive coronary artery disease were randomly divided into treatment group(n=55)and control group(n=56).After enrollment,all patients recorded the scores of the Seattle Angina Questionnaire(SAQ).The control group was given conventional treatment such as improving ischemic symptoms,anti-platelet,and lipid-lowering.On the basis of the treatment of the control group,the treatment group took Shexiang Tongxin Dropping Pill orally,70 mg each time,3 times a day.Coronary flow reserve(CFR)was rechecked after 6 months of treatment,and SAQ was used to evaluate the patient′s life quality.The safety indicators were measured once after 1 month and 6 months of drug treatment.Results:After 6 months of treatment,the CFR levels of the two groups were significantly improved(P<0.05),and the CFR level of the treatment group was better than that of the control group(P<0.05).The proportion of patients with CFR>2 in the treatment group was higher than that in the control group(29.1%vs 5.4%,P<0.05).The SAQ scores of the two groups of patients were significantly increased after drug treatment(P<0.05).And the SAQ scores of the treatment group was significantly higher than that of the control group during the same period(P<0.05).There was no significant difference in the incidence of major adverse cardiovascular events between the two groups during treatment(P>0.05).After 6 months of treatment,the heart rate and systolic blood pressure of the two groups were significantly reduced(P<0.05),and there was no significant difference between the two groups(P>0.05).Conclusion:Shexiang Tongxin Dropping Pill can improve microvascular function and life quality in CMVD patients,and has good reliability.